Trial Profile

Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMC-002 (Primary) ; Satricabtagene autoleucel (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors Suzhou Immunofoco Biotechnology

04 Jun 2024 Results(As of January 17, 2024) discussing preliminary safety and efficacy data for the pts dosed with up to 3 mil CAR-T cells/kg , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
01 Jun 2024 Results presented in an Immunofoco Biotech Media Release.
01 Jun 2024 According to an Immunofoco Biotech media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 31 to June 4, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com